Edwards Lifesciences

Global $12.2 Bn Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market to 2025

Retrieved on: 
Monday, August 20, 2018
Medicine, Cardiac surgery, Circulatory system, Clinical medicine, Percutaneous aortic valve replacement, Aortic valve, Aortic stenosis, Valve replacement, Heart valve, Edwards Lifesciences

The global transcatheter aortic valve replacement (TAVR) devices market size is anticipated to reach USD 12.2 billion by 2025, progressing at a CAGR of 22.6% during the forecast period.

Key Points: 
  • The global transcatheter aortic valve replacement (TAVR) devices market size is anticipated to reach USD 12.2 billion by 2025, progressing at a CAGR of 22.6% during the forecast period.
  • Increasing incidence of cardiovascular diseases and severe aortic stenosis disorder are among key factors augmenting the TAVR device market.
  • Moreover, rising number of various clinical trials such as Edwards SAPIEN 3 and Medtronic Transcatheter Aortic Valve 2.0 Replacement System are likely to contribute to the growth of the market during the forecast period.
  • Improvements in surgical techniques and quality of implantable valves are leading to an increase in the adoption of aortic valve replacement procedures.

Hemodynamic Monitoring Systems Market Worth $1,167.4 Million by 2023

Retrieved on: 
Monday, August 20, 2018
Health, Medicine, Edwards Lifesciences, Intensive care medicine, Monitoring, Ambulatory care

On the basis of type, the Hemodynamic Monitoring Systems Market is segmented into invasive, minimally invasive, and noninvasive systems.

Key Points: 
  • On the basis of type, the Hemodynamic Monitoring Systems Market is segmented into invasive, minimally invasive, and noninvasive systems.
  • On the basis of end user, the Hemodynamic Monitoring Systems Market is segmented into hospitals, clinics and ambulatory care centers (ACCs), and home care settings.
  • In 2018, North America is expected to account for the largest share of the Hemodynamic Monitoring Systems Market, followed by Europe.
  • The key players in the global Hemodynamic Monitoring Systems Market are Edwards Lifesciences Corporation (US), PULSION Medical Systems SE (Germany), LiDCO Group plc (UK), Cheetah Medical (Israel), Deltex Medical Group Plc.

The global transcatheter aortic valve replacement (TAVR) devices market size is anticipated to reach USD 12.2 billion by 2025

Retrieved on: 
Thursday, July 26, 2018
Medicine, Cardiac surgery, Circulatory system, Clinical medicine, Percutaneous aortic valve replacement, Valve replacement, Aortic valve, Aortic stenosis, Heart valve, John G. Webb, Edwards Lifesciences

LONDON, July 26, 2018 /PRNewswire/ -- Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Size, Share & Trends Analysis Report By Procedure (Transapical, Transfemoral, Transaortic), By Country, Vendor Landscape, And Segment Forecasts, 2018 - 2025

Key Points: 
  • LONDON, July 26, 2018 /PRNewswire/ -- Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Size, Share & Trends Analysis Report By Procedure (Transapical, Transfemoral, Transaortic), By Country, Vendor Landscape, And Segment Forecasts, 2018 - 2025
    The global transcatheter aortic valve replacement (TAVR) devices market size is anticipated to reach USD 12.2 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 22.6% during the forecast period.
  • Increasing incidence of cardiovascular diseases and severe aortic stenosis disorder are among key factors augmenting the TAVR device market.
  • Moreover, rising number of various clinical trials such as Edwards SAPIEN 3 and Medtronic Transcatheter Aortic Valve 2.0 Replacement System are likely to contribute to the growth of the market during the forecast period.
  • Improvements in surgical techniques and quality of implantable valves are leading to an increase in the adoption of aortic valve replacement procedures.

Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018

Retrieved on: 
Thursday, July 12, 2018
Edwards Lifesciences, Edwards, Irvine, California, Trademark, Property, Market economics)

For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13681143.

Key Points: 
  • For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13681143.
  • Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.
  • Edwards is a trademark of Edwards Lifesciences Corporation.
  • Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR

Retrieved on: 
Thursday, June 28, 2018
Edwards Lifesciences, Safety

This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.

Key Points: 
  • This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.
  • These forward-looking statements include, but are not limited to, expected impacts of the National Coverage Determination on product availability and patient access.
  • These filings, along with important safety information about our products, may be found at edwards.com .
  • Edwards and Edwards Lifesciences are trademarks of Edwards Lifesciences Corporation.

Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

Retrieved on: 
Tuesday, May 22, 2018
Edwards Lifesciences, Edwards, Valve

The Edwards SAPIEN 3 valve has been available in Europe since 2014 and in the United States since 2015.

Key Points: 
  • The Edwards SAPIEN 3 valve has been available in Europe since 2014 and in the United States since 2015.
  • In 2016, both European and U.S. regulators expanded the approval to include intermediate-risk patients.
  • The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves.
  • Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, PARTNER, PARTNER II, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.

Edwards Announces Key Events For EuroPCR 2018

Retrieved on: 
Monday, May 21, 2018
Edwards Lifesciences, Edwards, European Society of Cardiology

PARIS, May 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced key events for the company during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC).

Key Points: 
  • PARIS, May 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced key events for the company during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC).
  • Among the scheduled data presentations are three late-breaking clinical trials:
    CENTERA-EU: One-year outcomes assessing a novel self-expanding transcatheter heart valve On May 22, new one-year results of the self-expanding Edwards CENTERA valve will be discussed.
  • The Edwards CENTERA valve received CE Mark in February.
  • Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, CENTERA, Edwards SAPIEN, Edwards SAPIEN 3, PARTNER, PARTNER II, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.

Edwards Lifesciences Reports First Quarter Results

Retrieved on: 
Tuesday, April 24, 2018
Edwards Lifesciences, Edwards, Irvine, California, Earnings per share, Economy, Financial economics

IRVINE, Calif., April24, 2018 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March31, 2018.

Key Points: 
  • IRVINE, Calif., April24, 2018 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March31, 2018.
  • Diluted earnings per share for the quarter was $0.96 per share, while adjusted earnings per share grew 29.8 percent to $1.22.
  • For the quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $551.6 million, a 2.3 percent growth rate over the first quarter last year.
  • Edwards, Edwards Lifesciences, the stylized E logo, Edwards CENTERA, CENTERA, PARTNER, PARTNER 3, and HemoSphere are trademarks of Edwards Lifesciences Corporation.